Equities analysts expect that Biodel Inc. (NASDAQ:ALBO) will announce earnings per share (EPS) of ($0.85) for the current quarter, Zacks reports. Zero analysts have issued estimates for Biodel’s earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.76). The business is expected to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Biodel will report full year earnings of ($3.69) per share for the current fiscal year, with EPS estimates ranging from ($4.09) to ($3.38). For the next year, analysts forecast that the company will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.60) to ($2.65). Zacks’ EPS averages are an average based on a survey of analysts that cover Biodel.
Biodel (NASDAQ:ALBO) last released its quarterly earnings data on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02).
Several brokerages have commented on ALBO. Zacks Investment Research downgraded Biodel from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Cowen and Company began coverage on Biodel in a research report on Wednesday, August 16th. They set an “outperform” rating on the stock. ValuEngine downgraded Biodel from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Needham & Company LLC began coverage on Biodel in a research report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and set a $58.00 price target on shares of Biodel in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $40.33.
Biodel (NASDAQ:ALBO) traded up 1.7571% during mid-day trading on Friday, hitting $23.3329. The stock had a trading volume of 8,456 shares. The stock’s market cap is $207.24 million. The stock’s 50-day moving average price is $22.92 and its 200-day moving average price is $22.23. Biodel has a 12 month low of $14.00 and a 12 month high of $37.69.
An institutional investor recently raised its position in Biodel stock. Renaissance Technologies LLC boosted its stake in shares of Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 27.36% of the company’s stock.
Biodel Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.